Study demonstrates positive effects of RefluG Isorepair on reflux symptoms

Published: 2-Sep-2020
Digestion

A new clinical study has been recently published on RefluGTM Isorepair, a medical device for the treatment of gastroesophageal reflux disease developed by Giellepi Health Science

Background

Gastroesophageal reflux disease (GERD), defined as troublesome symptoms or mucosal damage resulting from the reflux of gastric content into the esophagus, is one of the most common gastrointestinal tract disorders with an estimated prevalence higher than 21% in Europe1, 28% in USA2 and up to 33% in Asia and Middle Est2.

The most common symptoms associated with GERD are heartburn and regurgitation; extra esophageal symptoms, including dysphagia, chronic cough, globus sensation, odynophagia, hoarseness, wheezing and nausea, may also occur.

There are two main forms of GERD called erosive reflux disease (ERD) and non-erosive reflux disease (NERD); the latter subcategory represents up to 70% of patients with typical reflux symptoms. Notably, NERD patients have a significant lower response rate to proton pump inhibitor (PPI) therapy3.

A clinical trial recently published in the European Journal of Gastroenterology and Hepatology4 was aimed to assess the efficacy of RefluG™ Isorepair in patients with NERD. (Ribaldone et al. 2020).

Methodology

The efficacy and tolerability of RefluG™ Isorepair has been assessed in a randomized, double blind placebo-controlled trial including 40 NERD patients.

Patients were treated for 2 consecutive weeks with either placebo or RefluG™ Isorepair (3 sachets per day after main meals or before bed).

The primary outcome was to evaluate the efficacy of treatments in terms of the proportion of patients with a significant remission of NERD symptoms (heartburn and regurgitation), defined as a total symptom score (TSS) reduction of at least 3 points assessed according to the 5-point Likert scale.

Secondary outcomes included reduction of Heartburn Severity Index, improvement of Health-Related Quality of life (SF-36 Questionnaire), safety and tolerability.

Study demonstrates positive effects of RefluG Isorepair on reflux symptoms

Findings

At the end of treatment, a 3-point reduction in the Total Symptoms Score (TSS) was achieved by 95% of patients treated with RefluG Isorepair, while only 20% of patients treated with placebo showed a 3-point reduction (P < 0.0001; fig. 1).

In patients taking RefluG™ Isorepair, TSS was decreased 68% at the end of the treatment vs baseline.

Heartburn severity index was found to be statistically lower among patients treated with the investigational product compared to those in the placebo group both at Day 7 (P < 0.0001) and at Day 14 (P < 0.0001). Unlike the placebo group, Quality of life was improved at the end of treatment in patients taking the investigational product.

Overall, RefluG™ Isorepair resulted safe and well tolerated; no adverse effects were observed in either of the study groups.

Conclusion

In NERD patients, RefluG™ Isorepair led to a statistically significant improvement in symptoms such as heartburn and regurgitation compared to placebo. Such symptomatic benefit is likely related to the strengthening of the esophageal barrier against the damage induced by gastric contents flowed back into the esophagus during reflux episodes.

Given its mechanism of action, this product may be used alone or in combination with the current pharmacological interventions for the management of GERD.

REFLUG™ ISOREPAIR in a nutshell

REFLUG™ ISOREPAIR is a unique patent-pending combination in liquid sachets registered as Medical Device Class IIA in Europe. Thanks to its protective effect, the product favors the natural healing of the mucosa reducing the unpleasant symptoms associated with acid reflux.

References

  1. Eusebi LH, Ratnakumaran R, Yuan Y, Solaymani-Dodaran M, Bazzoli F, Ford AC. Global prevalence of, and risk factors for, gastro-oesophageal reflux symptoms: a meta-analysis. Gut 2018;67:430–400.
  2. El-Serag HB, Sweet S, Winchester CC, Dent J. Update on the epidemiology of gastro-oesophageal reflux disease: a systematic review. Gut. 2014; 63(6):871-80.
  3. Hershcovici T & Fass R. Nonerosive Reflux Disease (NERD) - An Update. J Neurogastroenterol Motil. 2010; 16(1):8-21.
  4. Ribaldone et al. A randomized, double-blind, placebo-controlled pilot study to evaluate the efficacy and tolerability of a novel oral bioadhesive formulation for the treatment of non-erosive reflux disease-related symptoms. European Journal of Gastroenterology and Hepatology. August 2020, https://pubmed.ncbi.nlm.nih.gov/32804843/

  • Companies:
  • Biofarma Group
See more

You may also like

Digestion

Keep GERD symptoms at bay with RefluG Isorepair

Read more
Thanks to its novel mechanism of action, RefluG Isorepair helps to relieve acid reflux and protect the esophagus

Trending Articles

  1. Precision prebiotic reshapes microbiota composition, study finds The fermentation of BeniCaros resulted in an increased production of short-chain fatty acids — especially propionate — known to confer beneficial health effects on the host
  2. Augmenting digestive health with antioxidant power The antioxidant power of natural astaxanthin may offer a wide range of digestive health benefits. Scientific studies have demonstrated its capacity to reduce gastrointestinal problems and balance the intestinal flora, reports Pernilla Berg, Head of Research and Development at AstaReal
  3. Digestive health innovation: discover the untapped potential of DAO Anyone affected by digestive issues knows how difficult it can be to avoid certain triggers and find ways to ease any pain and discomfort. It’s even more problematic for those with food intolerances, reports Jaume Reguant, Healthcare Director at Bioiberica, who are often unable to enjoy the foods they love
  4. Microalgae-derived fucoxanthin: a powerful composition for liver health Clinical trials suggest fucoxanthin, the carotenoid found naturally in seaweed and microalgae, helps promote metabolic and liver health. Dr Tali Pechenick Jowers, Scientific Affairs Manager at Algatech, explains
  5. Kyowa Hakko's postbiotic for immune health named finalist in Ingredient of the Year IMMUSE proactively supports the immune system through a novel method of action that activates plasmacytoid dendritic cells (pDCs)

Upcoming event

Vitafoods Europe

14–16 May 2024 | Exhibition | Palexpo, Geneva See all

You may also like

Digestion

Keep GERD symptoms at bay with RefluG Isorepair

Thanks to its novel mechanism of action, RefluG Isorepair helps to relieve acid reflux and protect the esophagus
Ingredients

RefluG Isorepair: the new experience for oesophageal mucosal defence

RefluG Isorepair is a patented medical device (class IIa) with long-lasting action for the treatment of gastro-oesophageal reflux symptoms
Ingredients

The power of the pomegranate in bolstering gut health

Supplementation with Punica granatum extract can help to enhance gut health in three ways, a novel study finds
Ingredients

NutriLeads to showcase new Benicaros prebiotic options at Vitafoods Europe

The company will be showcasing the expansion of its precision prebiotic fibre range, as well as prototype ideas designed for immune and gut health fortification
Research & Development

Precision prebiotic reshapes microbiota composition, study finds

The fermentation of BeniCaros resulted in an increased production of short-chain fatty acids — especially propionate — known to confer beneficial health effects on the host
Research & Development

Diet and gut microbes linked mechanistically to IBD, study finds

Novel research unveils key mechanisms of inflammatory bowel disease with therapeutic implications
Ingredients

TriNutra receives Canadian Health Claims approval

Health Canada authorities have approved multiple structure-function health claims for ThymoQuin
Subscribe now